Analyst Reco. Elekta AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:29:35 03/05/2024 BST			5-day change	1st Jan Change
76.95 ^SEK	-0.06%		+1.79%	-6.52%

05-03	Elekta to Buy Philips Healthcare's Treatment Planning Patent Portfolio	MT
04-22	Elekta, GE HealthCare Team Up for New Cancer Treatment Planning Services	MT

ELEKTA : Elekta’s attractiveness reinforced	03-06
ELEKTA : Q3 miss; mid-to-longer term prospects remain promising	03-01
ELEKTA : Another quarterly beat; but market disappointment with the Q3 outlook	11-30
Chinese headwinds could be more severe than expected	22/09/23
ELEKTA : Taking into account possible challenges due to China's corruption crackdown	14/09/23
ELEKTA : Q1 exceeded expectations	24/08/23
ELEKTA : Strong end to the year	09/06/23
ELEKTA : Strong end to the year	25/05/23
ELEKTA : Strong Q3 + promising takeaways	24/02/23
Berenberg European Conference	06/12/22	FA
ELEKTA : Weakness persisted in Q2, but there’s hope of a turnaround	29/11/22
European shares struggle for direction as traders weigh rate outlook	24/11/22	RE
ELEKTA : Soft Q1; challenging market environment delaying business recovery	25/08/22
ELEKTA : Surprisingly, strong end to the year	25/05/22
ELEKTA : Supply-chain constraints delay performance recovery	24/02/22
ELEKTA : Supply-chain challenges weigh on Q3 results	14/02/22
Berenberg European Conference	08/12/21	FA
ELEKTA : Business recovery continues, although margin improvements warrant patience	25/11/21
Elekta receives initial investment grade rating from S&P Global Ratings	26/10/21	AQ
ELEKTA : Business recovery overshadowed by temporary cost headwinds	25/08/21

No results for this search

ELEKTA : Elekta’s attractiveness reinforced

March 06, 2024 at 04:06 pm